世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
新規T細胞免疫療法の世界市場シェアとランキング、全体売上高と需要予測 2024-2030Novel T Cell Immunotherapies - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 新規T細胞免疫療法の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に％のCAGRで2030年までに100万米ドルの再調整された規模になると予測されている。 新規T細胞免疫療... もっと見る
※当ページの内容はウェブ更新時の情報です。 
サマリー新規T細胞免疫療法の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に％のCAGRで2030年までに100万米ドルの再調整された規模になると予測されている。新規T細胞免疫療法の北米市場は、2023年に百万ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに百万ドルに達すると予測されます。 新規T細胞免疫療法のアジア太平洋市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに100万ドルに達するだろう。 新規T細胞免疫療法のヨーロッパ市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに100万ドルに達するだろう。 新規T細胞免疫療法の世界の主要企業には、Atara Biotherapeutics、Allovir、Eureka Therapeutics、Eutilex、Gammadelta Therapeutics、Neximmune、Ose Immunotherapeutics、Tevogen Bio、Windmil Therapeuticsなどがある。2023年には、世界の大手5社が売上高で約 %のシェアを占めている。 レポートの範囲 本レポートは、新規T細胞免疫療法の世界市場を包括的に紹介することを目的としており、地域別・国別、タイプ別、用途別の新規T細胞免疫療法の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当てています。 新規T細胞免疫療法の市場規模、推計、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データと予測データを売上高（百万ドル）で提供します。定量的・定性的分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、新規T細胞免疫療法に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。 市場区分 企業別 アタラ・バイオセラピューティクス アロビル エウレカ・セラピューティクス ユーティレックス ガンマデルタ・セラピューティクス ネクシミューン Oseイムノセラピューティクス テボジェンバイオ ウィンドミル・セラピューティクス タイプ別セグメント 活性化T細胞 ウイルス駆動型T細胞 トレグ T細胞ワクチン その他 用途別セグメント 肺がん 乳がん サイトメガロウイルス感染症 その他 地域別 北米 米国 カナダ 欧州 ドイツ フランス 英国 イタリア ロシア アジア太平洋 中国 日本 韓国 中国 台湾 東南アジア インド ラテンアメリカ メキシコ ブラジル アルゼンチン 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 各章の概要 第1章：報告書のスコープ、世界の総市場規模を紹介。本章ではまた、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章：新規T細胞免疫療法メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。 第3章：各種市場セグメントをタイプ別に分析し、各市場セグメントの市場規模や発展可能性を網羅し、読者が各市場セグメントにおけるブルーオーシャン市場を見つけやすくします。 第4章：読者が異なる川下市場におけるブルーオーシャン市場を見つけるのを助けるために、各市場セグメントの市場規模と発展の可能性をカバーする、アプリケーション別に様々な市場セグメントの分析を提供します。 第5章：地域レベルでの新規T細胞免疫療法の収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。 第6章：新規T細胞免疫療法の国別収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。 第7章：主要企業のプロファイルを提供し、製品収益、売上総利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。 第8章：産業の上流と下流を含む産業チェーンの分析。 第9章：結論 目次1 Market Overview1.1 Novel T Cell Immunotherapies Product Introduction 1.2 Global Novel T Cell Immunotherapies Market Size Forecast 1.3 Novel T Cell Immunotherapies Market Trends & Drivers 1.3.1 Novel T Cell Immunotherapies Industry Trends 1.3.2 Novel T Cell Immunotherapies Market Drivers & Opportunity 1.3.3 Novel T Cell Immunotherapies Market Challenges 1.3.4 Novel T Cell Immunotherapies Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Novel T Cell Immunotherapies Players Revenue Ranking (2023) 2.2 Global Novel T Cell Immunotherapies Revenue by Company (2019-2024) 2.3 Key Companies Novel T Cell Immunotherapies Manufacturing Base Distribution and Headquarters 2.4 Key Companies Novel T Cell Immunotherapies Product Offered 2.5 Key Companies Time to Begin Mass Production of Novel T Cell Immunotherapies 2.6 Novel T Cell Immunotherapies Market Competitive Analysis 2.6.1 Novel T Cell Immunotherapies Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Novel T Cell Immunotherapies Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel T Cell Immunotherapies as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Activated T-cells 3.1.2 Virus Driven T-cells 3.1.3 Tregs 3.1.4 T-cell Vaccines 3.1.5 Others 3.2 Global Novel T Cell Immunotherapies Sales Value by Type 3.2.1 Global Novel T Cell Immunotherapies Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Novel T Cell Immunotherapies Sales Value, by Type (2019-2030) 3.2.3 Global Novel T Cell Immunotherapies Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Lung Cancer 4.1.2 Breast Cancer 4.1.3 Cytomegalovirus Infection 4.1.4 Others 4.2 Global Novel T Cell Immunotherapies Sales Value by Application 4.2.1 Global Novel T Cell Immunotherapies Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Novel T Cell Immunotherapies Sales Value, by Application (2019-2030) 4.2.3 Global Novel T Cell Immunotherapies Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Novel T Cell Immunotherapies Sales Value by Region 5.1.1 Global Novel T Cell Immunotherapies Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Novel T Cell Immunotherapies Sales Value by Region (2019-2024) 5.1.3 Global Novel T Cell Immunotherapies Sales Value by Region (2025-2030) 5.1.4 Global Novel T Cell Immunotherapies Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Novel T Cell Immunotherapies Sales Value, 2019-2030 5.2.2 North America Novel T Cell Immunotherapies Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Novel T Cell Immunotherapies Sales Value, 2019-2030 5.3.2 Europe Novel T Cell Immunotherapies Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Novel T Cell Immunotherapies Sales Value, 2019-2030 5.4.2 Asia Pacific Novel T Cell Immunotherapies Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Novel T Cell Immunotherapies Sales Value, 2019-2030 5.5.2 South America Novel T Cell Immunotherapies Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Novel T Cell Immunotherapies Sales Value, 2019-2030 5.6.2 Middle East & Africa Novel T Cell Immunotherapies Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Novel T Cell Immunotherapies Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Novel T Cell Immunotherapies Sales Value 6.3 United States 6.3.1 United States Novel T Cell Immunotherapies Sales Value, 2019-2030 6.3.2 United States Novel T Cell Immunotherapies Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Novel T Cell Immunotherapies Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Novel T Cell Immunotherapies Sales Value, 2019-2030 6.4.2 Europe Novel T Cell Immunotherapies Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Novel T Cell Immunotherapies Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Novel T Cell Immunotherapies Sales Value, 2019-2030 6.5.2 China Novel T Cell Immunotherapies Sales Value by Type (%), 2023 VS 2030 6.5.3 China Novel T Cell Immunotherapies Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Novel T Cell Immunotherapies Sales Value, 2019-2030 6.6.2 Japan Novel T Cell Immunotherapies Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Novel T Cell Immunotherapies Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Novel T Cell Immunotherapies Sales Value, 2019-2030 6.7.2 South Korea Novel T Cell Immunotherapies Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Novel T Cell Immunotherapies Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Novel T Cell Immunotherapies Sales Value, 2019-2030 6.8.2 Southeast Asia Novel T Cell Immunotherapies Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Novel T Cell Immunotherapies Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Novel T Cell Immunotherapies Sales Value, 2019-2030 6.9.2 India Novel T Cell Immunotherapies Sales Value by Type (%), 2023 VS 2030 6.9.3 India Novel T Cell Immunotherapies Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Atara Biotherapeutics 7.1.1 Atara Biotherapeutics Profile 7.1.2 Atara Biotherapeutics Main Business 7.1.3 Atara Biotherapeutics Novel T Cell Immunotherapies Products, Services and Solutions 7.1.4 Atara Biotherapeutics Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.1.5 Atara Biotherapeutics Recent Developments 7.2 Allovir 7.2.1 Allovir Profile 7.2.2 Allovir Main Business 7.2.3 Allovir Novel T Cell Immunotherapies Products, Services and Solutions 7.2.4 Allovir Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.2.5 Allovir Recent Developments 7.3 Eureka Therapeutics 7.3.1 Eureka Therapeutics Profile 7.3.2 Eureka Therapeutics Main Business 7.3.3 Eureka Therapeutics Novel T Cell Immunotherapies Products, Services and Solutions 7.3.4 Eureka Therapeutics Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.3.5 Eutilex Recent Developments 7.4 Eutilex 7.4.1 Eutilex Profile 7.4.2 Eutilex Main Business 7.4.3 Eutilex Novel T Cell Immunotherapies Products, Services and Solutions 7.4.4 Eutilex Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.4.5 Eutilex Recent Developments 7.5 Gammadelta Therapeutics 7.5.1 Gammadelta Therapeutics Profile 7.5.2 Gammadelta Therapeutics Main Business 7.5.3 Gammadelta Therapeutics Novel T Cell Immunotherapies Products, Services and Solutions 7.5.4 Gammadelta Therapeutics Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.5.5 Gammadelta Therapeutics Recent Developments 7.6 Neximmune 7.6.1 Neximmune Profile 7.6.2 Neximmune Main Business 7.6.3 Neximmune Novel T Cell Immunotherapies Products, Services and Solutions 7.6.4 Neximmune Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.6.5 Neximmune Recent Developments 7.7 Ose Immunotherapeutics 7.7.1 Ose Immunotherapeutics Profile 7.7.2 Ose Immunotherapeutics Main Business 7.7.3 Ose Immunotherapeutics Novel T Cell Immunotherapies Products, Services and Solutions 7.7.4 Ose Immunotherapeutics Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.7.5 Ose Immunotherapeutics Recent Developments 7.8 Tevogen Bio 7.8.1 Tevogen Bio Profile 7.8.2 Tevogen Bio Main Business 7.8.3 Tevogen Bio Novel T Cell Immunotherapies Products, Services and Solutions 7.8.4 Tevogen Bio Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.8.5 Tevogen Bio Recent Developments 7.9 Windmil Therapeutics 7.9.1 Windmil Therapeutics Profile 7.9.2 Windmil Therapeutics Main Business 7.9.3 Windmil Therapeutics Novel T Cell Immunotherapies Products, Services and Solutions 7.9.4 Windmil Therapeutics Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.9.5 Windmil Therapeutics Recent Developments 8 Industry Chain Analysis 8.1 Novel T Cell Immunotherapies Industrial Chain 8.2 Novel T Cell Immunotherapies Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Novel T Cell Immunotherapies Sales Model 8.5.2 Sales Channel 8.5.3 Novel T Cell Immunotherapies Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
SummaryThe global market for Novel T Cell Immunotherapies was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030. Table of Contents1 Market Overview1.1 Novel T Cell Immunotherapies Product Introduction 1.2 Global Novel T Cell Immunotherapies Market Size Forecast 1.3 Novel T Cell Immunotherapies Market Trends & Drivers 1.3.1 Novel T Cell Immunotherapies Industry Trends 1.3.2 Novel T Cell Immunotherapies Market Drivers & Opportunity 1.3.3 Novel T Cell Immunotherapies Market Challenges 1.3.4 Novel T Cell Immunotherapies Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Novel T Cell Immunotherapies Players Revenue Ranking (2023) 2.2 Global Novel T Cell Immunotherapies Revenue by Company (2019-2024) 2.3 Key Companies Novel T Cell Immunotherapies Manufacturing Base Distribution and Headquarters 2.4 Key Companies Novel T Cell Immunotherapies Product Offered 2.5 Key Companies Time to Begin Mass Production of Novel T Cell Immunotherapies 2.6 Novel T Cell Immunotherapies Market Competitive Analysis 2.6.1 Novel T Cell Immunotherapies Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Novel T Cell Immunotherapies Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Novel T Cell Immunotherapies as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Activated T-cells 3.1.2 Virus Driven T-cells 3.1.3 Tregs 3.1.4 T-cell Vaccines 3.1.5 Others 3.2 Global Novel T Cell Immunotherapies Sales Value by Type 3.2.1 Global Novel T Cell Immunotherapies Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Novel T Cell Immunotherapies Sales Value, by Type (2019-2030) 3.2.3 Global Novel T Cell Immunotherapies Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Lung Cancer 4.1.2 Breast Cancer 4.1.3 Cytomegalovirus Infection 4.1.4 Others 4.2 Global Novel T Cell Immunotherapies Sales Value by Application 4.2.1 Global Novel T Cell Immunotherapies Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Novel T Cell Immunotherapies Sales Value, by Application (2019-2030) 4.2.3 Global Novel T Cell Immunotherapies Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Novel T Cell Immunotherapies Sales Value by Region 5.1.1 Global Novel T Cell Immunotherapies Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Novel T Cell Immunotherapies Sales Value by Region (2019-2024) 5.1.3 Global Novel T Cell Immunotherapies Sales Value by Region (2025-2030) 5.1.4 Global Novel T Cell Immunotherapies Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Novel T Cell Immunotherapies Sales Value, 2019-2030 5.2.2 North America Novel T Cell Immunotherapies Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Novel T Cell Immunotherapies Sales Value, 2019-2030 5.3.2 Europe Novel T Cell Immunotherapies Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Novel T Cell Immunotherapies Sales Value, 2019-2030 5.4.2 Asia Pacific Novel T Cell Immunotherapies Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Novel T Cell Immunotherapies Sales Value, 2019-2030 5.5.2 South America Novel T Cell Immunotherapies Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Novel T Cell Immunotherapies Sales Value, 2019-2030 5.6.2 Middle East & Africa Novel T Cell Immunotherapies Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Novel T Cell Immunotherapies Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Novel T Cell Immunotherapies Sales Value 6.3 United States 6.3.1 United States Novel T Cell Immunotherapies Sales Value, 2019-2030 6.3.2 United States Novel T Cell Immunotherapies Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Novel T Cell Immunotherapies Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Novel T Cell Immunotherapies Sales Value, 2019-2030 6.4.2 Europe Novel T Cell Immunotherapies Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Novel T Cell Immunotherapies Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Novel T Cell Immunotherapies Sales Value, 2019-2030 6.5.2 China Novel T Cell Immunotherapies Sales Value by Type (%), 2023 VS 2030 6.5.3 China Novel T Cell Immunotherapies Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Novel T Cell Immunotherapies Sales Value, 2019-2030 6.6.2 Japan Novel T Cell Immunotherapies Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Novel T Cell Immunotherapies Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Novel T Cell Immunotherapies Sales Value, 2019-2030 6.7.2 South Korea Novel T Cell Immunotherapies Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Novel T Cell Immunotherapies Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Novel T Cell Immunotherapies Sales Value, 2019-2030 6.8.2 Southeast Asia Novel T Cell Immunotherapies Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Novel T Cell Immunotherapies Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Novel T Cell Immunotherapies Sales Value, 2019-2030 6.9.2 India Novel T Cell Immunotherapies Sales Value by Type (%), 2023 VS 2030 6.9.3 India Novel T Cell Immunotherapies Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Atara Biotherapeutics 7.1.1 Atara Biotherapeutics Profile 7.1.2 Atara Biotherapeutics Main Business 7.1.3 Atara Biotherapeutics Novel T Cell Immunotherapies Products, Services and Solutions 7.1.4 Atara Biotherapeutics Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.1.5 Atara Biotherapeutics Recent Developments 7.2 Allovir 7.2.1 Allovir Profile 7.2.2 Allovir Main Business 7.2.3 Allovir Novel T Cell Immunotherapies Products, Services and Solutions 7.2.4 Allovir Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.2.5 Allovir Recent Developments 7.3 Eureka Therapeutics 7.3.1 Eureka Therapeutics Profile 7.3.2 Eureka Therapeutics Main Business 7.3.3 Eureka Therapeutics Novel T Cell Immunotherapies Products, Services and Solutions 7.3.4 Eureka Therapeutics Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.3.5 Eutilex Recent Developments 7.4 Eutilex 7.4.1 Eutilex Profile 7.4.2 Eutilex Main Business 7.4.3 Eutilex Novel T Cell Immunotherapies Products, Services and Solutions 7.4.4 Eutilex Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.4.5 Eutilex Recent Developments 7.5 Gammadelta Therapeutics 7.5.1 Gammadelta Therapeutics Profile 7.5.2 Gammadelta Therapeutics Main Business 7.5.3 Gammadelta Therapeutics Novel T Cell Immunotherapies Products, Services and Solutions 7.5.4 Gammadelta Therapeutics Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.5.5 Gammadelta Therapeutics Recent Developments 7.6 Neximmune 7.6.1 Neximmune Profile 7.6.2 Neximmune Main Business 7.6.3 Neximmune Novel T Cell Immunotherapies Products, Services and Solutions 7.6.4 Neximmune Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.6.5 Neximmune Recent Developments 7.7 Ose Immunotherapeutics 7.7.1 Ose Immunotherapeutics Profile 7.7.2 Ose Immunotherapeutics Main Business 7.7.3 Ose Immunotherapeutics Novel T Cell Immunotherapies Products, Services and Solutions 7.7.4 Ose Immunotherapeutics Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.7.5 Ose Immunotherapeutics Recent Developments 7.8 Tevogen Bio 7.8.1 Tevogen Bio Profile 7.8.2 Tevogen Bio Main Business 7.8.3 Tevogen Bio Novel T Cell Immunotherapies Products, Services and Solutions 7.8.4 Tevogen Bio Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.8.5 Tevogen Bio Recent Developments 7.9 Windmil Therapeutics 7.9.1 Windmil Therapeutics Profile 7.9.2 Windmil Therapeutics Main Business 7.9.3 Windmil Therapeutics Novel T Cell Immunotherapies Products, Services and Solutions 7.9.4 Windmil Therapeutics Novel T Cell Immunotherapies Revenue (US$ Million) & (2019-2024) 7.9.5 Windmil Therapeutics Recent Developments 8 Industry Chain Analysis 8.1 Novel T Cell Immunotherapies Industrial Chain 8.2 Novel T Cell Immunotherapies Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Novel T Cell Immunotherapies Sales Model 8.5.2 Sales Channel 8.5.3 Novel T Cell Immunotherapies Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野の最新刊レポート
QYResearch 社の最新刊レポート本レポートと同じKEY WORD（）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/07/05 10:26 162.17 円 175.82 円 209.73 円 |